Ulcerative colitis and colorectal cancer. A population-based study
- PMID: 2215606
- DOI: 10.1056/NEJM199011013231802
Ulcerative colitis and colorectal cancer. A population-based study
Abstract
Background: The risk of colorectal cancer is increased among patients with ulcerative colitis. The magnitude of this increase in risk and the effects of the length of follow-up, the extent of disease at diagnosis, and age at diagnosis vary substantially in different studies.
Methods: To provide accurate estimates of the risk of colorectal cancer among patients with ulcerative colitis, we studied a population-based cohort of 3117 patients given a diagnosis of ulcerative colitis from 1922 through 1983 who were followed up through 1984.
Results: Ninety-two cases of colorectal cancer occurred in 91 patients. As compared with the expected incidence, the incidence of colorectal cancer in the cohort was increased (standardized incidence ratio [ratio of observed to expected cases] = 5.7; 95 percent confidence interval, 4.6 to 7.0). Less extensive disease at diagnosis was associated with a lower risk; for patients with ulcerative proctitis, the standardized incidence ratio was 1.7 (95 percent confidence interval, 0.8 to 3.2); for those with left-sided colitis, 2.8 (95 percent confidence interval, 1.6 to 4.4); and for those with pancolitis (extensive colitis, or inflammation of the entire colon), 14.8 (95 percent confidence interval, 11.4 to 18.9). Age at diagnosis and the extent of disease at diagnosis were strong and independent risk factors for colorectal cancer. For each increase in age group at diagnosis (less than 15 years, 15 to 29 years, 30 to 39 years, 40 to 49 years, 50 to 59 years, and greater than or equal to 60 years), the relative risk of colorectal cancer, adjusted for the extent of disease at diagnosis, decreased by about half (adjusted standardized incidence ratio = 0.51; 95 percent confidence interval, 0.46 to 0.56). The absolute risk of colorectal cancer 35 years after diagnosis was 30 percent for patients with pancolitis at diagnosis and 40 percent for those given this diagnosis at less than 15 years of age.
Conclusions: Close surveillance and perhaps even prophylactic proctocolectomy should be recommended for patients given a diagnosis of pancolitis, especially those who are less than 15 years of age at diagnosis.
Similar articles
-
Studies in longstanding ulcerative colitis with special reference to malignant transformation of the colorectal mucosa.Acta Chir Scand Suppl. 1989;552:1-45. Acta Chir Scand Suppl. 1989. PMID: 2800882
-
[Long-term prognosis of patients with ulcerative colitis].Ugeskr Laeger. 1993 Nov 15;155(46):3767-72. Ugeskr Laeger. 1993. PMID: 8256373 Danish.
-
Ulcerative colitis in Stockholm County--a study of epidemiology, prognosis, mortality and cancer risk with special reference to a surveillance program.Acta Chir Scand Suppl. 1986;534:1-60. Acta Chir Scand Suppl. 1986. PMID: 3472421
-
Chronic inflammatory bowel disease and cancer.Hepatogastroenterology. 2000 Jan-Feb;47(31):57-70. Hepatogastroenterology. 2000. PMID: 10690586 Review.
-
Clinical course of ulcerative colitis.Dig Liver Dis. 2008 Jul;40 Suppl 2:S247-52. doi: 10.1016/S1590-8658(08)60533-2. Dig Liver Dis. 2008. PMID: 18598996 Review.
Cited by
-
MicroRNA-224 negatively regulates p21 expression during late neoplastic progression in inflammatory bowel disease.Inflamm Bowel Dis. 2013 Mar;19(3):471-80. doi: 10.1097/MIB.0b013e31827e78eb. Inflamm Bowel Dis. 2013. PMID: 23399735 Free PMC article.
-
The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis.Cell Death Differ. 2013 Nov;20(11):1485-97. doi: 10.1038/cdd.2013.76. Epub 2013 Jul 12. Cell Death Differ. 2013. PMID: 23852374 Free PMC article.
-
Therapeutic dosages of aspirin counteract the IL-6 induced pro-tumorigenic effects by slowing down the ribosome biogenesis rate.Oncotarget. 2016 Sep 27;7(39):63226-63241. doi: 10.18632/oncotarget.11441. Oncotarget. 2016. PMID: 27557515 Free PMC article.
-
Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk?World J Gastroenterol. 2012 Aug 7;18(29):3839-48. doi: 10.3748/wjg.v18.i29.3839. World J Gastroenterol. 2012. PMID: 22876036 Free PMC article. Review.
-
Riboflavin depletion of intestinal cells in vitro leads to impaired energy generation and enhanced oxidative stress.Eur J Nutr. 2013 Aug;52(5):1513-21. doi: 10.1007/s00394-012-0458-6. Epub 2012 Nov 6. Eur J Nutr. 2013. PMID: 23868757
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials